St. Jude (STJ +1.9%) estimates adjusted Q4 EPS of $0.97-0.99, with both ends of the range 2 cents above previous guidance. However, the figures exclude about $0.55 a share in charges, mainly related to restructuring and other corporate costs.
St. Jude also expects revenue to have risen to $1.42B from $1.37B.
Analysts project EPS of $0.96 and sales of $1.38B.
Sales breakdown: Cardiac Rhythm Management +3% to $705M; Atrial Fibrillation +5% to $252M; Cardiovascular +4% to $350M; Neuromodulation +2% to $115M.
St. Jude is due to give a presentation at the Annual JPMorgan Healthcare Conference in San Francisco at 11 PST. (PR)
"Our Q3 results demonstrate that we are successfully implementing our program to accelerate sales growth on a sustainable basis," St. Jude Medical (STJ) CEO Daniel Starks says, regarding the company's MRQ performance.
Stripping out currency impact, STJ's Q3 sales grew 3% Y/Y.
On a segment-by-segment basis (currency neutral): CRM sales were essentially flat at $682M, AF sales rose 7% to $235M, cardiovascular sales jumped 4% to $317M, and neuromodulationsales were up around 3% to $104M.
Outlook: Q4 EPS of $0.95-0.97 on revenue of $1.315B-1.395B versus consensus of $0.96/share on sales of $1.39B. For the full year: EPS of $3.72-3.74 on sales of $5.394-5.474B against consensus of $3.72/share and revenue of $5.45B. (PR)
More on St. Jude Medical (STJ +2.1%) Q2: net profit -53% to $115M, hurt by charges of $160M, primarily related to debt retirement. Adjusted net profit flat at $275M. Net sales also flat. Sales breakdown: Cardiac Rhythm Management -4% to $718M; Atrial Fibrillation +9% to $237M; Cardiovascular flat at $340M; neuromodulation +2% to $108M. Guidance: Q3 EPS of $0.88-0.90 vs consensus of $0.88; FY EPS of $3.70-3.73, increasing the lower range by $0.02 from prior forecast and vs analyst predictions of $3.69. (PR)
St. Jude Medical, Inc., develops, manufactures and distributes cardiovascular medical devices for global cardiac rhythm management, cardiovascular, atrial fibrillation therapy areas and neurostimulation medical devices for the management of chronic pain.